Anti-PD-L1 treatment increases tumour-specific CD8⁺ T cell infiltration and promotes effector function within tumours.

<p>A-G) B16.mOVA cells (10⁵) were injected s.c. to 11c.OVA mice and 3 days later OT-I Tcm-phenotype cells (5 x 10⁶) transferred i.v. OT-I recipients were injected on the day of OT-I transfer and every subsequent 3 days with isotype control or αPD-L1 mAb as indicated. Twelve days after OT-I Tcm-phenotype cell transfer, spleen (A, E), tumour draining LN (TDLN) (B), and tumour (C, D, F, G) were harvested and OT-I (CD45.1⁺/CD8⁺/Vα2⁺) number and cytokine production determined using a flow-cytometric counting assay (A, B, C, D) and intracellular cytokine staining (E, F) or a combination of both. Data represent individual mice pooled from 2 experiments of 2–3 mice per group.